52results about How to "Arresting its development" patented technology

Methods for treating peptic ulcers and methods for treating gastroesophageal reflux disease by oral administration of a botulinum toxin.

The present invention relates to improvements in the field of drug delivery. More particularly, the invention relates to a non-invasive and flexible method and carrier for transporting a compound or drug across the blood-brain barrier of an individual. In particular the present invention relates to a carrier for transporting an agent attached thereto across a blood-brain barrier, wherein the carrier is able to cross the blood-brain barrier after attachment to the agent and thereby transport the agent across the blood-brain barrier. The present invention relates to improvements in the field of drug delivery. More particularly, the invention relates to a non-invasive and flexible method and carrier for transporting a compound or drug across the blood-brain barrier of an individual. In particular the present invention relates to a carrier for transporting an agent attached thereto across a blood-brain barrier, wherein the carrier is able to cross the blood-brain barrier after attachment to the agent and thereby transport the agent across the blood-brain barrier.

The present invention provides dietary formulations comprising polyunsaturated fatty acids and vitamin E. The present invention further provides methods of treating various conditions, generally involving administering to an individual in need thereof an effective amount of a subject dietary formulation.

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure.

The present invention provides methods of treating a fibrotic disorder. The methods generally involve administering an effective amount of IFN-γ and an effective amount of pirfenidone or a pirfenidone analog.

The invention provides method and compositions for determining the presence and amount of a virus such as HIV-1, HIV-2, Hepatitis B, Hepatitis C, RSV, Rotavirus A, and M. tuberculosis in a sample. Also provided are methods for determining whether a subject is infected with HIV, as well as, the type. The methods involve contacting a sample from the subject with a PDZ polypeptide (PDZ) or other PL binding factor and/or PDZ ligands (PL) and determining whether binding interactions occur between PDZ or other binding factor and PL. Assays for identifying anti-viral and anti-bacterial agents are also provided, as well as, methods for using the compositions to alter PDZ binding to PL in viral or bacterial infected cells.

The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having insulin-like growth factor-1 deficiency (IGFD). The invention relates to methods comprising administering insulin-like growth factor-I to a patient having a height which, at the time of treatment or prior to initial treatment with IGF-1, is at least about 2 standard deviations below normal for a subject of the same age and gender, a blood level of insulin-like growth factor-I that, and at the time of treatment or prior to initial treatment with IGF-1, is below normal mean levels, usually at least about 1 standard deviations below normal mean levels, for age and gender.

Methods and compositions for determining whether a subject at least has a neoplastic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a soluble filamin analyte, such as a filamin A analyte, to determine whether the subject at least has the neoplastic disease. Also provided are kits, systems, and devices for practicing the subject methods.

The invention relates to a pharmaceutical composition consisting of snail slime of Helix aspersa muller (Cryptophalus aspersus) (5% to 50%), chamomile extract (5% to 10%), honey (5% to 10%), and additives and/or pharmaceutically accepted excipients to form a formulation having low, intermediate or high viscosity (1 to 1000 Pa·s). By dipping a patch or bandage of gauzy fabric into the composition in the form of a lotion, shampoo, soap, cream or gel, the composition is applied on lesions caused by psoriasis. The composition can also contain natural extracts, such as marigold extract, propolis, and vegetable oils. The invention also claims a method for obtaining the composition and the use thereof to prepare a drug or device for preventing, treating or curing psoriasis lesions on the head, the skin of the body or of the face.

The invention relates to a pharmaceutical composition consisting of snail slime Helix aspersa muller (Cryptomphalus aspersus) (20% to 50%), camomile extract (1-4%), propolis 1l-4%), and pharmaceutically acceptable excipients and/or additives for forming a formulation of low, intermediate or high viscosity (10 to 1000 Pa-s). Said composition is in the form of a lotion, soap, cream or gel, which is embedded in a gauze-type fabric in the form of a plaster that can be applied to lesions caused by the different types of rosacea. The composition can also contain natural extracts such as marigold extract, honey and vegetable oils. The invention also relates to the method for producing the composition and to the use thereof for preparing a medicament or device for preventing, treating or curing lesions caused by rosacea, on the skin of the face or the body.

The present invention provides methods for treating individuals having an HCV infection, which individuals have failed to respond to therapy with an INF-α other than consensus interferon (CIFN), or who, following cessation of therapy with an INF-α other than CIFN, have suffered relapse. The methods generally involve a dosage regimen involving administering a dose of CIFN and a dose of ribavirin for a period of time, where the dosage regimen is effective to achieve a sustained viral response in the individual.

The invention relates to a new neurotensin analogue, or a salt thereof, useful for targeting to neurotensin receptor-positive tumors, like ductal pancreatic adenocarcinoma, exocrine pancreatic cancer, invasive ductal breast cancers, colon adeno-carcinoma, small cell lung carcinoma, Ewing sarcoma, meningioma, medulloblastoma and astrocytoma.

Use of muscle-enriched/specific microRNAs for the treatment of sarcomas, as for example rhabdomyosarcomas, synovial sarcoma, alveolar soft part sarcoma, liposarcoma, and osteosarcoma, wherein the microRNAs are able to stop the development of neoplastic cells and to force the neoplastic cells to differentiate into terminally differentiated muscle cells.

Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described. A dose of ganaxolone is administered to a female suffering from postpartum depression or at risk of developing postpartum depression in an amount and at a rate sufficient to alleviate at least one symptom of postpartum depression in the female.

The present invention provides methods for treating individuals having a hepatitis C virus (HCV) infection, which individuals have failed to respond to therapy with an IFN-α other than consensus interferon (CIFN), or who, following cessation of therapy with an IFN-α other than CIFN, have suffered relapse. The methods generally involve a treatment regimen comprising administering a first dosing regimen of CIFN, followed by a second dosing regimen of CIFN. Ribavirin is administered with at least the second dosing regimen.

The disclosure generally relates to a therapeutic approach based on the stimulation of resolution of inflammation by the Formyl-Peptide Receptor 2/Lipoxin A₄ receptor (FPR2/ALX) for the treatment of heart disease.

Methods for preventing, reversing, ameliorating or treating dental diseases, disorders or injuries are provided. In particular, methods for preventing, reversing, ameliorating or treating dental diseases of the gingival (gums) and bone are provided. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents.

The invention provides methods and compositions for identifying modulators, particularly peptide modulators, of cell surface receptor activity. Specifically, the invention provides a cell containing a recombinant nucleic acid encoding a polypeptide modified for intracellular presentation, which cell may further comprise one or both of a recombinant nucleic acid encoding a binding partner for that polypeptide and recombinant nucleic acid encoding a test polypeptide. The subject cell may be a member of a library of cells, and the library may be used in screening methods for identifying test polypeptides (e.g., conformationally restrained polypeptides) having cell surface receptor modulatory activity. The invention finds use in a variety of drug-discovery applications.

The invention relates to nucleic acid agents modulating the expression of SLAMF6 isoforms, compositions comprising same and methods for their use in immunomodulation. Specifically, provided are splice-switching oligonucleotides and constructs useful in cancer immunotherapy.

Methods and formulations are provided for treating or preventing arthritis, in particular osteoarthritis, where the formulation to be administered to a subject for treating or preventing arthritis comprises carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins. The invention provides methods of treating or preventing arthritis, such as osteoarthritis, in a subject in need thereof comprising administering to the subject a formulation or composition comprising carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins in an amount effective to treat or prevent arthritis.